McDermott helps biotech company in licensing agreement
McDermott, Will & Emery represented South Korean biotechnology company PharmAbcine Inc. in its licensing agreement with Triphase Accelerator Corp. Per terms of the agreement, Toronto- and San Diego-based research and development company Triphase received certain global development and commercial rights for a compound related to the treatment of multiple forms of cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
